BioInvent and Merck Present Updated Data on BI-1808 and Keytruda Combination

BioInvent and Merck presented updated data from a clinical trial on the combination of BI-1808 and Keytruda for treating advanced platinum-resistant recurrent ovarian cancer at the ESMO Congress 2026. The trial included 34 evaluable patients, showing durable responses and a low rate of treatment-related discontinuations, indicating the combination therapy was well-tolerated.